References
- Järbe TUC, Gifford RS. Herbal incense: designer drug blends as cannabimimetics and their assessment by drug discrimination and other in vivo bioassays. Life Sci. 2014;97:64–71.
- Elsohly MA, Gul W, Wanas AS, et al. Synthetic cannabinoids: analysis and metabolites. Life Sci. 2014;97:78–90.
- United Nations Office on Drug and Crime (UNODC) report. Synthetic cannabinoids in herbal products; [cited 2016 Jan 6]. Available from: https://www.unodc.org/documents/scientific/Synthetic_Cannabinoids.pdf.
- Fantegrossi WE, Moran JH, Radominska-Pandya A, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ9-THC: mechanism underlying greater toxicity? Life Sci. 2014;97:45–54.
- Castaneto MS, Gorelick DA, Desrosiers NA, et al. Synthetic cannabinoids: epidemiology, pharmacodynamics and clinical implications. Drug Alcohol Depend. 2014;144:12–41.
- Atwood BK, Lee D, Straiker A, et al. CP47,497-C8 and JWH073, commonly found in 'spice' herbal blends, are potent and efficacious CB(1) cannabinoid receptor agonists. Eur J Pharmacol. 2011;659:139–145.
- Spaderna M, Addy PH, D'Souza DC. Spicing things up: synthetic cannabinoids. Psychopharmacology (Berl). 2013;228:525–540.
- Monaghan M. Drug policy governance in the UK: lessons from changes to and debates concerning the classification of cannabis under the 1971 misuse of drugs act. Int J Drug Policy. 2014;25:1025–1030.
- Fattore L, Fratta W, Beyond THC. The new generation of cannabinoid designer drugs. Front Behav Neurosci. 2011;60:1–12.
- Gurney SMR, Scott KS, Kacinko KS, et al. Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs. Forensic Sci Rev. 2014;26:53–77.
- Aung MM, Griffin G, Huffman JW, et al. Influence of the N-1 alkyl chain length of cannabimimetic indoles upon CB(1) and CB(2) receptor binding. Drug Alcohol Depend. 2000;60:133–140.
- Auwärter V, Dresen S, Weinmann W, et al. Spice and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom. 2009;44:832–837.
- Louh IK, Freeman WD. A spicy encephalopathy: synthetic cannabinoids as cause of encephalopathy and seizure. Crit Care. 2014;18:553–554.
- Mir A, Obafemi A, Young A, et al. Myocardial infarction associated with use of the synthetic cannabinoid K2. Pediatrics. 2011;128:e1622–e1627.
- Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. 2013;6:330–333.
- Harris CR, Brown A. Synthetic cannabinoid intoxication: a case series and review. J Emerg Med. 2013;44:360–366.
- Wells DL, Ott CA. The new marijuana. Ann Pharmacother. 2011;45:414–417.
- Dunne FJ, Jaffar K, Hashmi S. Legal highs - not so new and still growing in popularity. BJMP 2015;8:a801.
- Gunderson EW. Synthetic cannabinoids: a new frontier of designer drugs. Ann Intern Med. 2013;159:563–564.
- Schneir AB, Baumbacher T. Convulsions associated with the use of a synthetic cannabinoid product. J Med Toxicol. 2012;8:62–64.
- Law R, Schier J, Martin C, Chang A, Wolkin A. Increase in reported adverse health effects related to synthetic cannabinoid use. MMWR. 2015;64:618–619.
- Wood KE. Exposure to bath salts and synthetic tetrahydrocannabinol from 2009 to 2012 in the United States. J Pediatr. 2013;163:213–216.
- National Poisons Information Service Report 2013/2014; [cited 2016 Jan 6]. Available from: http://www.npis.org/NPISAnnualReport2013-14.pdf.
- Advisory Council on the Misuse of Drugs. Consideration of the major cannabinoid agonists 2009; [cited 2016 Jan 6]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119149/acmd-report-agonists.pdf.
- Advisory Council of the Misuse of Drugs, Further consideration of the synthetic cannabinoids 2012; [cited 2016 Jan 6]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/119042/synthetic-cannabinoids-2012.pdf.
- Advisory Council of the Misuse of Drugs. Third generation synthetic Cannabinoids 2014; [cited 2016 Jan 6]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/380161/CannabinoidsReport.pdf.
- Welsh Emerging Drugs and Identification of Novel Substances (WEDINOS) project. Substance Information; [cited 2016 Jan 6]. Available from: www.wedinos.org/db/samples.
- Persson HE, Sjoberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol Clin Toxicol. 1998;36:205–213.
- Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the national poison data system in 2010. Ann Emerg Med. 2012;60:435–438.
- Forrester M, Kleinschmidt K, Schwarz E, et al. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol. 2012;31:1–6.
- Brown J, Gunja N, Buckley N. Synthetic cannabinoids: impact of Australian legislation: is the problem Kronic or chronic? Clin Toxicol. 2014;52:364–365.
- Hermanns-Clausen M, Kneisel S, Szabo B, et al. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings. Addiction. 2013;108:534–544.
- Locatelli CA, Lonati D, Giampreti A, et al. New synthetic cannabinoids intoxications in Italy: clinical identification and analytical confirmation of cases. Eur J Emerg Med. 2011;18:309.
- Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54:1–13.
- Dines AM, Wood DM, Galicia M, et al. Presentations to the emergency department following cannabis use a multi-centre case series from ten European countries. J Med Toxicol. 2015;11:415–421.
- Centers for Disease Control and Prevention (CDC). Acute kidney injury associated with synthetic cannabinoid use-multiple States. MMWR. 2013;62:93–96.
- Dargan PI, Hudson S, Ramsey J, et al. The impact of changes in UK classification of the synthetic cannabinoid receptor agonists in spice. Int J Drug Policy. 2011;22:274–277.
- Wiegand TJ, Marraffa J, Gorodetsky RM, et al. Comparison of psychoactive bath salt and synthetic cannabinoid cases pre- and post-federal legislative ban - evidence of effective control measures in New York state. J Med Toxicol. 2013;9:102.
- Herbert JX, Duggan E, Tracey JA. The effect of legislation on synthetic cannabinoid abuse in Ireland. Clin Toxicol (Phila). 2011;49:240.
- Drugwatch information sheet (version 1.5). Potent Synthetic Cannabinoid smoking mixtures; [cited 2016 Jan 6]. Available from: http://www.sdf.org.uk/index.php/download_file/view/671/106/.